GenCurix Files International Patent Application for Bladder Cancer Liquid Biopsy Diagnostic Technology Using Biomarkers

[Asia Economy Reporter Hyunseok Yoo] Liquid biopsy molecular diagnostics specialist GenCurix announced on the 28th that it has filed an international patent for the discovery of biomarkers and bladder cancer detection technology for bladder cancer diagnosis.

The name of the technology for which the patent was filed is "Composition for diagnosing bladder cancer using CpG (cytosine-guanine sequence) methylation changes of specific genes and its use." The company had already completed the domestic application in January last year.

A GenCurix official stated, "This patent relates to the selection of bladder cancer-specific methylation biomarkers present in DNA in blood or urine and bladder cancer diagnostic technology using them," adding, "By utilizing the biomarkers of this patent, it is expected to be continuously used for early diagnosis tests of bladder cancer as well as for monitoring cancer progression and recurrence in the future." He emphasized, "We will accelerate product research and development based on a high level of accuracy and sensitivity."

Meanwhile, GenCurix announced on the 27th that it plans to complete clinical trials for early diagnosis liquid biopsy technology for liver cancer and colorectal cancer within this year and proceed with domestic and international approvals. Once the ongoing clinical trials are completed, the company plans to initiate procedures for approval from the Korean Ministry of Food and Drug Safety as well as global authorizations within the year.

This content was produced with the assistance of AI translation services.